Literature DB >> 33670929

Fertility-Sparing Surgery in Gynecologic Cancer: A Systematic Review.

Teska Schuurman1, Sanne Zilver2, Sanne Samuels1, Winnie Schats3, Frédéric Amant1,4, Nienke van Trommel1, Christianne Lok1.   

Abstract

Fertility-sparing surgery (FSS) is increasingly being offered to women with a gynecological malignancy who wish to preserve fertility. In this systematic review, we evaluate the best evidence currently available on oncological and reproductive outcome after FSS for early stage cervical cancer, epithelial ovarian cancer, and endometrial cancer. An extensive literature search was conducted using the electronic databases Medline (OVID), Embase, and Cochrane Library to identify eligible studies published up to December 2020. In total, 153 studies were included with 7544, 3944, and 1229 patients who underwent FSS for cervical, ovarian, and endometrial cancer, respectively. We assessed the different FSS techniques that are available to preserve fertility, i.e., omitting removal of the uterine body and preserving at least one ovary. Overall, recurrence rates after FSS are reassuring and therefore, these conservative procedures seem oncologically safe in the current selection of patients with low-stage and low-grade disease. However, generalized conclusions should be made with caution due to the methodology of available studies, i.e., mostly retrospective cohort studies with a heterogeneous patient population, inducing selection bias. Moreover, about half of patients do not pursue pregnancy despite FSS and the reasons for these decisions have not yet been well studied. International collaboration will facilitate the collection of solid evidence on FSS and the related decision-making process to optimize patient selection and counseling.

Entities:  

Keywords:  adolescents and young adults; cervical cancer; conization; endometrial cancer; fertility-sparing surgery; hormonal therapy; ovarian cancer; trachelectomy

Year:  2021        PMID: 33670929     DOI: 10.3390/cancers13051008

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  6 in total

1.  Analysis of the Correlation between Nutritional Status and Quality of Life of Patients with Gynaecological Ovarian Cancer during Postoperative Chemotherapy.

Authors:  Xiaoming Shi; Yuchun Lv; Peiqi Wang; Xin Yang; Shengjun You
Journal:  J Oncol       Date:  2022-06-22       Impact factor: 4.501

2.  Outcomes of the First Pregnancy After Fertility-Sparing Surgery for Early-Stage Cervical Cancer.

Authors:  Roni Nitecki; Jessica Floyd; Kelly Lamiman; Mark A Clapp; Shuangshuang Fu; Kirsten Jorgensen; Alexander Melamed; Paula C Brady; Anjali Kaimal; Marcela G Del Carmen; Terri L Woodard; Larissa A Meyer; Sharon H Giordano; Pedro T Ramirez; J Alejandro Rauh-Hain
Journal:  Obstet Gynecol       Date:  2021-10-01       Impact factor: 7.623

Review 3.  Fertility after Cancer: Risks and Successes.

Authors:  Chiara Di Tucci; Giulia Galati; Giulia Mattei; Alessandra Chinè; Alice Fracassi; Ludovico Muzii
Journal:  Cancers (Basel)       Date:  2022-05-19       Impact factor: 6.575

Review 4.  Biomolecular and Genetic Prognostic Factors That Can Facilitate Fertility-Sparing Treatment (FST) Decision Making in Early Stage Endometrial Cancer (ES-EC): A Systematic Review.

Authors:  Panayiotis Tanos; Savvas Dimitriou; Giuseppe Gullo; Vasilios Tanos
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

5.  Matrine exerts antitumor activity in cervical cancer by protective autophagy via the Akt/mTOR pathway in vitro and in vivo.

Authors:  Fan Zhang; Hua Zhang; Wenjun Qian; Yuyan Xi; Lihua Chang; Xiaoling Wu; Mu Li
Journal:  Oncol Lett       Date:  2022-02-07       Impact factor: 2.967

Review 6.  Contemporary Fertility-Sparing Management Options of Early Stage Endometrioid Endometrial Cancer in Young Nulliparous Patients.

Authors:  Gulzhanat Aimagambetova; Sanja Terzic; Antonio Simone Laganà; Gauri Bapayeva; Philip la Fleur; Milan Terzic
Journal:  J Clin Med       Date:  2021-12-30       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.